Appleby acted as Cayman Islands counsel for Mega Genomics Limited (Mega Genomics) on its listing on the Main Board of the Hong Kong Stock Exchange on 22 June 2022, with gross proceeds of approximately HKD215 million.

The Appleby team was led by Partner Chris Cheng and assisted by Partner Vincent Chan and Legal Executive Connie Wu.

Mega Genomics is a leading genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services.

Mega Genomics intends to use the net proceeds from the Global Offering for promotion, research and development of its services and products, expansion of its testing capability and capacity, working capital and other general corporate purposes.

Our Hong Kong Capital Markets team is highly regarded for their extensive expertise in supporting offshore companies with IPOs, introductions, placements and listings of both equity and debt securities on the Hong Kong, US, Singapore and many other internationally recognised stock exchanges.